Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

ABLYNX (ABLX)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Ablynx : Belgian biotech Ablynx scores big hit with blood disease drug

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/02/2017 | 10:15am CET

Belgian biotech company Ablynx reported resoundingly positive data for an experimental drug against a rare blood disorder on Monday, sending its market value above $1.1 billion (£825 million).

Ablynx said its caplacizumab medicine met the primary and secondary goals in a late-stage trial testing the treatment in patients with acquired thrombotic thrombocytopenic purpura (aTTP).

This included a 74 percent relative reduction in the percentage of patients with aTTP-related death, a recurrence of aTTP or at least one major thromboembolic event during the study drug treatment period.

Shares in Ablynx jumped 25 percent in early trade on what Jefferies analysts described as near best-case results.

The brokerage assumes caplacizumab will launch in mid-2018 in Europe and the first half of 2019 in the United States and will generate worldwide peak sales of $400 million. Caplacizumab is wholly-owned by Ablynx, so sales should be highly profitable.

"These results strengthen our resolve to obtain marketing approval as quickly as possible so that caplacizumab rapidly becomes available to patients suffering from this severe disease for which there is currently no approved drug available," said Ablynx CEO Edwin Moses.

(Reporting by Ben Hirschler; Editing by Edmund Blair)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABLYNX
12/12 ABLYNX : 12/12/2017 ablynx reports additional clinically important benefits of c..
12/12 ABLYNX : Reports additional clinically important benefits of caplacizumab from i..
12/07 ABLYNX : Will host a webcast to discuss additional data from its phase iii hercu..
11/29 ABLYNX : 29/11/2017 publication in accordance with article 14 of the belgian law..
11/29 ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
11/21 ABLYNX : 21/11/2017 results from the phase iii hercules study of caplacizumab fo..
11/21 ABLYNX : Results from the phase iii hercules study of caplacizumab for the treat..
11/16 ABLYNX : 16/11/2017 ablynx announces results for the first nine months of 2017 a..
11/16 ABLYNX : Announces results for the first nine months of 2017 and a year-to-date ..
11/15 ABLYNX : 15/11/2017 publication in accordance with article 14 of the belgian law..
More news
News from SeekingAlpha
12/07 Ablynx to update on Phase 3 study of caplacizumab December 12
11/16 Ablynx NV reports 9M results
10/18 YOUR DAILY PHARMA SCOOP : AZN's Imfinzi SBLA; Ablynx U.S. IPO; Is Teva A Buy?
10/17 Ablynx prices $175M U.S. IPO at $20.95
10/04 3 THINGS IN BIOTECH YOU SHOULD LEARN : October 4, 2017
Financials (€)
Sales 2017 64,7 M
EBIT 2017 -56,2 M
Net income 2017 -73,4 M
Finance 2017 203 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 20,4x
EV / Sales 2018 23,6x
Capitalization 1 524 M
Chart ABLYNX
Duration : Period :
Ablynx Technical Analysis Chart | ABLX | BE0003877942 | 4-Traders
Technical analysis trends ABLYNX
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 23,6 €
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
Edwin Moses Chief Executive Officer & Executive Director
Peter John Fellner Chairman
Wim Ottevaere Chief Financial Officer
Antonin Rollet de Fougerolles Chief Scientific Officer
Robert K. Zeldin Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ABLYNX86.59%1 802
CELLTRION, INC.--.--%23 699
IQVIA HOLDINGS INC32.70%21 261
INCYTE CORPORATION-3.68%20 703
LONZA GROUP57.44%20 102
ALNYLAM PHARMACEUTICALS, INC.249.60%12 278